医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

FUJIFILM VisualSonics Unveils the Ultimate Pre-Clinical Imaging Experience with the Vevo® 3100 at the World Molecular Imaging Congress Annual Meeting

2014年09月17日 PM10:00
このエントリーをはてなブックマークに追加


 

TORONTO

(Booth #510) – FUJIFILM VisualSonics Inc., a world leader in real time, in vivo, high-resolution micro-imaging systems designed specifically for pre-clinical research and subsidiary of FUJIFILM SonoSite, Inc., will unveil the world’s first one-touch pre-clinical imaging platform, the Vevo® 3100 on September 17 -20 at the World Molecular Imaging Congress Annual Meeting in Seoul, Korea.

“Equipped with new Vevo HD Image Technology, a customizable touchscreen user interface, and onboard learning, the Vevo® 3100 imaging platform allows researchers to experience a new and efficient method of imaging in the pre-clinical research world,” said Naohiro Fujitani, President & CEO, FUJIFILM SonoSite, Inc. “As the undisputed leader in real-time in vivo micro-imaging systems, FUJIFILM VisualSonics once again advances the world of pre-clinical research with the launch of the Vevo® 3100 imaging platform.”

Touch technology on the Vevo® 3100 imaging platform offers the ultimate preclinical imaging experience in medical research. The unique, gesture-driven user interface can be personalized by multiple users and is easily controlled with the glide of a finger and without keys or buttons. Its intuitive control panel allows customizable workflow for rapid data acquisition, providing extremely high throughput when needed.

The simplicity encourages novice and advanced users alike to attain high quality images provided with the new Vevo HD Image Technology equipped on the system. This real-time image processing algorithm allows researchers to visualize high-resolution data like never before. It reduces speckle noise and artifacts in images while preserving and enhancing critical tissue information. The innovative platform also combines real-time learning with onboard step-by-step imaging tutorials and guides.

With smart engineering and a minimalist design, the Vevo® 3100 has a reduced foot print and weight by 40 percent that encourages portability and navigation of this capital instrument in high traffic and unique research environments to conduct ground breaking science. Lightweight ergonomically designed MX series transducers, are also available and are custom-designed and optimized to operate in harmony with the Vevo® 3100 imaging system. The transducers are available across a range of frequencies to provide flexibility that is needed for small animal studies.

This revolutionary technology provides researchers with an easy to use imaging modality that allows them to obtain in vivo anatomical, functional, physiological and molecular data simultaneously, all in real-time and with a resolution down to 30 μm.

The Vevo Imaging solutions have witnessed over 1000 peer-reviewed published reports of advancing science and medical research. The future of preclinical imaging research will witness unmatched contributions with the Vevo® 3100 in research on high value diseases. As the trusted leader in real time, in vivo micro-imaging systems, FujiFilm VisualSonics redefines deep tissue imaging for research on disease characterization, therapeutic efficacies and pharmacology.

For more information, please visit: http://www.visualsonics.com/.

About Fujifilm

FUJIFILM VisualSonics, Inc., is the world leader in real time, in vivo, high-resolution micro imaging systems designed specifically for preclinical research. The company’s cutting edge technologies allow researchers at the world’s most prestigious pharmaceutical and biotechnology companies, hospitals and universities to conduct research in cardiovascular, cancer, neurobiology and developmental biology areas. The micro imaging technologies support research applications that include genetic research, phenotypic studies and drug development. VisualSonics high-frequency ultrasound and photoacoustic platforms combine high-resolution, real time in vivo imaging at reasonable cost with ease-of-use and quantifiable results. VisualSonics is a subsidiary of FUJIFILM SonoSite, Inc.

FUJIFILM SonoSite, Inc., is the innovator and world leader in bedside and point-of-care ultrasound, and an industry leader in ultra high-frequency micro-ultrasound technology. Headquartered near Seattle, the company is represented by 26 subsidiaries and a global distribution network in over 100 countries. SonoSite’s portable, compact systems are expanding the use of ultrasound across the clinical spectrum by cost-effectively bringing high-performance ultrasound to the point of patient care. For more information, go to: www.sonosite.com.

FUJIFILM Holdings Corporation, Tokyo, Japan brings continuous innovation and leading-edge products to a broad spectrum of industries, including: healthcare, with medical systems, pharmaceuticals and cosmetics; graphic systems; highly functional materials, such as flat panel display materials; optical devices, such as broadcast and cinema lenses; digital imaging; and document products. These are based on a vast portfolio of chemical, mechanical, optical, electronic, software and production technologies. In the year ended March 31, 2014, the company had global revenues of $23.9 billion, at an exchange rate of 102 yen to the dollar. Fujifilm is committed to environmental stewardship and good corporate citizenship. For more information, please visit: www.fujifilmholdings.com.

All product and company names herein may be trademarks of their registered owners.

CONTACT

Fujifilm
Lauren Geloso, (914) 789-8303
lgeloso@fujifilm.com

同じカテゴリーの記事 

  • C2N Diagnostics Expands Into Japan Through Mediford Corporation Partnership With Precivity™ Blood Testing for Alzheimer’s Disease and Brain Research Market
  • BeiGene Demonstrates Global Progress in 2023 Responsible Business & Sustainability Report
  • Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer
  • joimax® Obtains Registration for All Products in the Indian Market
  • Avistone Announces the Approval of Vebreltinib as the First MET-TKI Treatment for a Rare Brain Glioma Subtype in China